|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF)
| Title: | Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF) |
| Authors: | Yokota, Takashi Browse this author →KAKEN DB | | Fukushima, Arata Browse this author →KAKEN DB | | Kinugawa, Shintaro Browse this author →KAKEN DB | | Okumura, Takahiro Browse this author | | Murohara, Toyoaki Browse this author →KAKEN DB | | Tsutsui, Hiroyuki Browse this author →KAKEN DB |
| Keywords: | BNP | | Oxidative stress | | Xanthine oxidase inhibitor |
| Issue Date: | 1-Sep-2018 |
| Publisher: | International Heart Journal Association |
| Journal Title: | International Heart Journal |
| Volume: | 59 |
| Issue: | 5 |
| Start Page: | 976 |
| End Page: | 982 |
| Publisher DOI: | 10.1536/ihj.17-560 |
| Abstract: | Hyperuricemia is an independent predictor of mortality in patients with chronic heart failure. The aim of the study is to determine whether a urate-lowering agent febuxostat, an inhibitor of xanthine oxidase, may improve the clinical outcomes in chronic heart failure patients with hyperuricemia when compared to conventional treatment. This multicenter, prospective, randomized, open-label, blinded endpoint study with a follow-up period of 24 weeks will enroll 200 Japanese chronic heart failure patients with hyperuricemia. The eligibility criteria include a diagnosis of chronic heart failure (New York Heart Association functional class II-III with a history of hospitalization due to worsening of heart failure within the last 2 years), reduced left ventricular systolic function (left ventricular ejection fraction < 40%) and increased plasma natriuretic peptide [plasma B-type natriuretic peptide (BNP) ? 100 pg/mL or N-terminal pro BNP (NT-proBNP) ? 400 pg/mL], and hyperuricemia (serum uric acid >7.0 mg/dL and ? 10 mg/dL) at the screening visit. The primary outcome is the difference in the plasma BNP levels between the baseline and 24 weeks of treatment. The plasma BNP levels are measured in the central laboratory in a blinded manner. This study investigates the efficacy and safety of febuxostat in chronic heart failure patients with hyperuricemia. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/76941 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
